Moneyball Medicine

Harry welcomes back Andrew A. Radin, CEO of the drug discovery startup twoXAR, where scientists model pathogenesis computationally to identify potential drug molecules, ideally shaving years off the drug development process.Harry first spoke with Radin two years ago at the AI Applications Summit—Biopharma. (Listen back to MoneyBall Medicine Episode 9 from November 2018 for more details about the company's innovations.) Since then, the company has begun to use what Radin calls twoXAR's "discovery engine" to test hypotheses about new drug leads in 18 different treatment areas, counting a dozen internal programs."We go after complex disease where we think there is not only an unmet medical need, but where we believe discovery of new biology can  unlock some opportunity for new therapy," Radin tells Harry. He says the company's approach compresses the time-consuming early steps of basic science, literature search,  hypothesis formulation, and high-throughput screening into a single computational step. "We're goin